Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis

被引：0
作者：
Smolen, J. [1 ]
Beaulieu, A. [2 ]
Rubbert-Roth, A. [3 ]
Alecock, E. [4 ]
Alten, R. [5 ]
Woodworth, T. [4 ]
机构：
[1] Univ Clin Internal Med, Clin Dept Pheumatol, Vienna, Austria
[2] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada
[3] Univ Cologne, Med Clin 1, Cologne, Germany
[4] Roche Prod Ltd, Welwyn, SK, Canada
[5] Charite Univ Med Berlin, Schlosspk Clin, Dept Internal Med 2, D-13353 Berlin, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
[31]   Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis [J].
Hashimoto, Motomu ;
Fujii, Takao ;
Hamaguchi, Masahide ;
Furu, Moritoshi ;
Ito, Hiromu ;
Terao, Chikashi ;
Yamamoto, Keiichi ;
Yamamoto, Wataru ;
Matsuo, Takashi ;
Mori, Masato ;
Ohmura, Koichiro ;
Kawabata, Hiroshi ;
Mimori, Tsuneyo .
PLOS ONE, 2014, 9 (05)
[32]   Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs [J].
Semerano, Luca ;
Thiolat, Allan ;
Minichiello, Emeline ;
Clavel, Gaelle ;
Bessis, Natacha ;
Boissier, Marie-Christophe .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (07) :979-999
[33]   The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment [J].
Butsabong Lerkvaleekul ;
Sirisucha Soponkanaporn ;
Soamarat Vilaiyuk .
Pediatric Rheumatology, 12 (Suppl 1)
[34]   Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis [J].
Hirohata, Shunsei ;
Abe, Asami ;
Murasawa, Akira ;
Kanamono, Toshihisa ;
Tomita, Tetsuya ;
Yoshikawa, Hideki .
MODERN RHEUMATOLOGY, 2017, 27 (05) :766-772
[35]   A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis [J].
Shuntaro Saito ;
Katsuya Suzuki ;
Keiko Yoshimoto ;
Yuko Kaneko ;
Yoshihiro Matsumoto ;
Kunihiro Yamaoka ;
Tsutomu Takeuchi .
Arthritis Research & Therapy, 19
[36]   A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis [J].
Saito, Shuntaro ;
Suzuki, Katsuya ;
Yoshimoto, Keiko ;
Kaneko, Yuko ;
Matsumoto, Yoshihiro ;
Yamaoka, Kunihiro ;
Takeuchi, Tsutomu .
ARTHRITIS RESEARCH & THERAPY, 2017, 19
[37]   IL6 Correlates with Clinical Disease Activity in Patients with Rheumatoid Arthritis [J].
Milman, Nataliya ;
Booth, Ronald ;
Karsh, Jacob .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) :2577-2577
[38]   IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab [J].
Tanaka, Yoshiya ;
Martin Mola, Emilio .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (09) :1595-1597
[39]   Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity [J].
van Herwaarden, N. ;
Herfkens-Hol, S. ;
van der Maas, A. ;
van den Bemt, B. J. F. ;
van Vollenhoven, R. F. ;
Bijlsma, J. W. J. ;
den Broeder, A. A. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (03) :390-394
[40]   The influence of anti-human IL-6 receptor antibody on bone metabolism in rheumatoid arthritis patients [J].
Hashimoto, J ;
Tsuboi, H ;
Yoshikawa, H ;
Tomita, T ;
Ochi, T ;
Yoshizaki, K ;
Nishimoto, N .
ARTHRITIS AND RHEUMATISM, 2001, 44 (09) :S216-S216
12345